Sino Biopharmaceutical Performance dei guadagni passati

Il passato criteri di controllo 4/6

Gli utili di Sino Biopharmaceutical sono diminuiti a un tasso medio annuo di -13.6%, mentre il settore Pharmaceuticals ha visto gli utili crescere a un tasso medio annuo di 5.7%. I ricavi sono cresciuti crescere a un tasso medio annuo di 2.9%. Il ritorno sul capitale proprio di Sino Biopharmaceutical è 12% e ha margini netti di 7.7%.

Informazioni chiave

-13.6%

Tasso di crescita degli utili

-13.4%

Tasso di crescita dell'EPS

Pharmaceuticals Crescita del settore	5.6%
Tasso di crescita dei ricavi	2.9%
Rendimento del capitale proprio	12.0%
Margine netto	7.7%
Ultimo aggiornamento sui guadagni	30 Jun 2024

Aggiornamenti sulle prestazioni recenti

Recent updates

Ripartizione dei ricavi e delle spese

Come Sino Biopharmaceutical guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.

Storia dei guadagni e delle entrate

SZSC:1177 Ricavi, spese e utili (CNY Millions )
Data	Ricavi	Guadagni	Spese G+A
30 Jun 24	27,790	2,142	11,689
31 Mar 24	26,995	1,995	11,378
31 Dec 23	26,199	1,847	11,067
30 Jun 23	25,116	1,254	11,001
31 Mar 23	25,571	1,656	11,355
31 Dec 22	26,026	2,059	11,709
30 Sep 22	28,241	5,296	12,705
30 Jun 22	27,701	8,049	12,846
31 Mar 22	27,215	13,655	12,669
31 Dec 21	26,861	14,608	12,704
30 Sep 21	26,129	12,465	12,718
30 Jun 21	25,353	10,011	12,754
31 Mar 21	24,668	3,809	12,198
31 Dec 20	23,647	2,771	11,629
30 Sep 20	23,039	2,302	11,254
30 Jun 20	24,354	2,558	11,490
31 Mar 20	24,248	2,781	11,762
31 Dec 19	24,234	2,762	11,797
30 Sep 19	24,479	9,101	12,544
30 Jun 19	23,691	9,125	11,801
31 Mar 19	22,444	9,132	11,036
31 Dec 18	20,889	9,046	10,268
30 Sep 18	19,103	2,567	8,799
30 Jun 18	17,062	2,436	7,921
31 Mar 18	15,609	2,363	7,334
31 Dec 17	14,819	2,171	6,905
30 Sep 17	14,491	2,115	6,680
30 Jun 17	14,258	1,862	6,668
31 Mar 17	13,899	1,789	6,525
31 Dec 16	13,543	1,637	6,493
30 Sep 16	13,271	1,674	6,344
30 Jun 16	12,858	1,604	6,272
31 Mar 16	12,507	1,575	6,084
31 Dec 15	12,189	1,490	5,974
30 Sep 15	12,030	1,432	5,994
30 Jun 15	11,124	1,447	5,483
31 Mar 15	10,552	1,263	5,252
31 Dec 14	9,900	1,210	4,933
30 Sep 14	9,205	1,074	4,457
30 Jun 14	8,876	951	4,366
31 Mar 14	8,434	886	4,287
31 Dec 13	7,731	809	3,945

Guadagni di qualità: 1177 ha guadagni di alta qualità.

Margine di profitto in crescita: Gli attuali margini di profitto netti di 1177 (7.7%) 1177 sono più alti rispetto allo scorso anno (5%).

Flusso di cassa libero e analisi degli utili

Analisi della crescita degli utili nel passato

Andamento degli utili: Gli utili di 1177 sono diminuiti del 13.6% all'anno negli ultimi 5 anni.

Accelerare la crescita: La crescita degli utili di 1177 nell'ultimo anno ( 70.9% ) supera la media quinquennale ( -13.6% all'anno).

Guadagni vs Settore: La crescita degli utili 1177 nell'ultimo anno ( 70.9% ) ha superato la percentuale del settore Pharmaceuticals 9.4%.

Sino Biopharmaceutical Performance dei guadagni passati

Il passato criteri di controllo 4/6

Informazioni chiave

Aggiornamenti sulle prestazioni recenti

First half 2024 earnings released: EPS: CN¥0.077 (vs CN¥0.06 in 1H 2023)

First half 2024 earnings released: EPS: CN¥0.16 (vs CN¥0.068 in 1H 2023)

Sino Biopharmaceutical Limited to Report Q2, 2024 Results on Aug 13, 2024

Full year 2023 earnings released: EPS: CN¥0.10 (vs CN¥0.11 in FY 2022)

Full year 2023 earnings released: EPS: CN¥0.10 (vs CN¥0.14 in FY 2022)

Sino Biopharmaceutical Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

Recent updates

Sino Biopharmaceutical Limited Announces Acceptance of New Indication Application for Marketing of Anlotinib Hydrochloride Capsule in Combination with Penpulimab Injection for First-Line Treatment of Advanced Hepatocellular Carcinoma

Sino Biopharmaceutical Limited Announces Approval for Clinical Trials of the Fourth-Generation EGFR Inhibitor "TQB3002" in the United States

Sino Biopharmaceutical Limited Announces Acceptance of New Indication Application for Marketing of Anlotinib Hydrochloride Capsules in Combination with Chemotherapy for First-Line Treatment of Advanced Soft Tissue Sarcoma

Key Executive recently sold HK$51m worth of stock

First half 2024 earnings released: EPS: CN¥0.077 (vs CN¥0.06 in 1H 2023)

Sino Biopharmaceutical Limited Announces Phase III Study Results of Culmerciclib in Combination with Fulvestrant for Treatment of HR+/HER2- Advanced Breast Cancer Following Endocrine Treatment Presented At 2024 CSCO

Sino Biopharmaceutical Limited Announces Phase III Study Results of Anlotinib Hydrochloride Capsules in Combination with Penpulimab Injection for First-Line Treatment of Advanced Hepatocellular Cancinoma Was Presented at ESMO 2024

Upcoming dividend of HK$0.03 per share

Sino Biopharmaceutical Limited Announces Positive Results on Phase III Study of Anlotinib Hydrochloride Capsule in Combination with Penpulimab for First-Line Treatment of Advanced Hepatocellular Carcoma

First half 2024 earnings released: EPS: CN¥0.16 (vs CN¥0.068 in 1H 2023)

Sino Biopharmaceutical Limited Announces Acceptance of New Indication Application for Marketing of Benmelstobart Injection in Combination with Anlotinib Hydrochloride Capsule for First-Line Treatment of Advanced Renal Cell Carinoma

Sino Biopharmaceutical Limited to Report Q2, 2024 Results on Aug 13, 2024

Sino Biopharmaceutical Limited Announces Interim Analysis of Phase III Clinical Trial of the Categroy 1 Innovative Drug Culmerciclib Capsule

Sino Biopharmaceutical Limited Announces Positive Results on Phase III Study of Anlotinib Hydrochloride Capsule in Combination with Chemotherapy for First-Line Treatment of Advanced Soft Tissue Sarcoma

Sino Biopharmaceutical Limited Announces Acceptance of New Drug Application for Categroy 1 Innovative Drug Rovadicitinib Tablet

Sino Biopharmaceutical Limited Receives Approval for Marketing of Liraglutide Injection

Sino Biopharmaceutical Limited Announces Approval for Marketing of Category 1 Innovative Drug Envonalkib Citrate Capsules "Envonalkib (TQ-B3139)"

Sino Biopharmaceutical Limited Announces Approval for Marketing of Gadoteridol Injection

Sino Biopharmaceutical Limited Announces Retirement of Ms. Li Mingqin as Executive Director

Upcoming dividend of HK$0.03 per share

Sino Biopharmaceutical Limited Announces Positive Results on Phase III Study of Benmelstobart Injection in Combination with Anlotinib Hydrochloride Capsules for First-Line Treatment of Advanced Renal Cell Carcinoma

Sino Biopharmaceutical Limited Receives Marketing Approval from National Medical Products Administration of China

Full year 2023 earnings released: EPS: CN¥0.10 (vs CN¥0.11 in FY 2022)

Sino Biopharmaceutical Limited Announces Approval for Marketing of Category 1 Unecritinib Fumarate Capsules

Executive Chairwoman of the Board recently bought HK$5.8m worth of stock

Sino Biopharmaceutical Limited, Annual General Meeting, Jun 05, 2024

Full year 2023 earnings released: EPS: CN¥0.10 (vs CN¥0.14 in FY 2022)

Sino Biopharmaceutical Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 5 July 2024

Sino Biopharmaceutical Limited Provides Update on Development Progress of Mash Products "Lanifibranor" and "TQA2225"

Sino Biopharmaceutical Limited Announces Latest Results of Phase II Clinical Study of KRAS G12C Inhibitor Garsorasib Tablet

Sino Biopharmaceutical Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

Sino Biopharmaceutical Limited Announces Acceptance of the New Indication Application for Marketing of Anlotinib Hydrochloride Capsules and Anti Pd-L1 Benmelstobart

Qingdao Ocean Innovative Products Investment Fund Co., Ltd. and Qingdao Ocean New Kinetic Energy Products Investment Fund (Limited Partnership) agreed to acquire 67% stake in CP Pharmaceutical (Qingdao) Co., Ltd from Sino Biopharmaceutical Limited (SEHK:1177) for CNY 1.8 billion.

Sino Biopharmaceutical Limited Announces Prioritised Evaluation Granted for KRAS G12c Inhibitor Garsorasib Tablet (D-1553)

Now 21% undervalued

Sino Biopharmaceutical Limited Announces Approval of Clinical Trial for Neuropathic Pain

Sino Biopharmaceutical Limited Announces Completion of Patient Enrollment in Phase III Clinical Trial of Anlotinib Combined with Chemotherapy in First-Line Treatment of Advanced Soft Tissue Sarcoma

Sino Biopharmaceutical Limited Announces Phase I Clinical Research Results of Tqh2722

Sino Biopharmaceutical Limited Announces First Dose of the First Batch of Subjects in Phase I Clinical Trial of TQA3038

An unknown buyer acquired Suzhou Tianqing Xingwei Med./Lianyungang Chia Tai Tianqing Med./Zhejia Tianqing Zhongwei Med. from Sino Biopharmaceutical Limited (SEHK:1177) for approximately CNY 150 million.

Investor sentiment improves as stock rises 16%

Sino Biopharmaceutical Limited Announces Application for Phase Ib/II Clinical Trial of Innovative Drug

An unknown buyer acquired 84.2% stake in Shanghai Chia Tai Tongyong Pharmaceutical Co., Ltd. from Sino Biopharmaceutical Limited (SEHK:1177) for CNY 290 million.

Upcoming dividend of HK$0.02 per share at 2.7% yield

Sino Biopharmaceutical Limited Announces IND Application of Innovative Medicine TRD205 (AT2R Antibody) Filed with and Accept by FDA

First half 2023 earnings released: EPS: CN¥0.068 (vs CN¥0.10 in 1H 2022)

Sino Biopharmaceutical Limited Announces Interim Cash Dividend for the Period Ended 30 June 2023, Payable on 27 October 2023

Sino Biopharmaceutical Limited to Report First Half, 2023 Results on Aug 25, 2023

Key Executive recently bought HK$34m worth of stock

Sino Biopharmaceutical Limited Announces Application for Marketing of Loxoprofen Sodium Cataplasms

Upcoming dividend of HK$0.06 per share at 3.0% yield

Sino Biopharmaceutical Limited Announces New Drug Marketing Application for the Category 1 Innovative Anti-Tumor Medicine

Sino Biopharmaceutical Limited Announces Approval for Marketing by National Medical Products Administration of China for F-627 (Efbemalenograstim alfa Injection)

Executive Vice Chairwoman of the Board recently bought HK$21m worth of stock

Full year 2022 earnings released: EPS: CN¥0.14 (vs CN¥0.78 in FY 2021)

Sino Biopharmaceutical Limited Announces Clinical Trial Application of Innovative Medicine "Tqb2103 (Claudin18.2 ADC)" Accepted by Center for Drug Evaluation

Sino Biopharmaceutical Limited Announces Application for Marketing of Category I Innovative Drug Tqb2450 Injection in Combination with Anlotinib Hydrochloride Capsules for the Indication of First-Line Treatment of Small Cell Lung Cancer

Sino Biopharmaceutical Limited Announces the Enrollment of All Patients in Phase III Clinical Trial of "Tqg203"

Less than half of directors are independent

Sino Biopharmaceutical Limited Provides Revenue Guidance for 2023

Upcoming dividend of HK$0.06 per share

Sino Biopharmaceutical Limited Announces Interim Cash Dividend for the period ended 30 June 2022, Payable on 28 September 2022

First half 2022 earnings released: EPS: CN¥0.10 (vs CN¥0.45 in 1H 2021)

Sino Biopharmaceutical Limited to Report First Half, 2022 Results on Aug 23, 2022

Sino Biopharmaceutical Limited Announces CEO Changes, Effective July 28, 2022

Sino Biopharmaceutical Limited Announces Application for Marketing of Category 1 Anti-Tumor Innovative Drug TQ-B3101 Capsule

Sino Biopharmaceutical Limited Announces Approval of Category 1 Innovative Drug TQC2938 Injection for Clinical Trial

Upcoming dividend of HK$0.04 per share

Sino Biopharmaceutical Submits Application for Marketing of the Category I Anti-Tumor Innovative Drug "TQ-B3139"